Abemaciclib, in combination with anastrozole (an aromatase inhibitor), results in increased adaptive immune response signatures that are phenotypic of increased T cell activation and antigen presentation even in early-stage HR+HER2- breast cancer, providing optimism for ongoing clinical trials in HR2+HER2- disease (Supplementary Table S2) [111]. Here, ERBB2 is linked to breast carcinoma.